-
2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid
-
ChemBase ID:
154735
-
Molecular Formular:
C26H33NO5
-
Molecular Mass:
439.54392
-
Monoisotopic Mass:
439.23587316
-
SMILES and InChIs
SMILES:
CC(C)c1ccc(cc1)COC(=O)N1CCC[C@H](C1)c1cccc(c1)OC(C)(C)C(=O)O
Canonical SMILES:
O=C(N1CCC[C@H](C1)c1cccc(c1)OC(C(=O)O)(C)C)OCc1ccc(cc1)C(C)C
InChI:
InChI=1S/C26H33NO5/c1-18(2)20-12-10-19(11-13-20)17-31-25(30)27-14-6-8-22(16-27)21-7-5-9-23(15-21)32-26(3,4)24(28)29/h5,7,9-13,15,18,22H,6,8,14,16-17H2,1-4H3,(H,28,29)/t22-/m1/s1
InChIKey:
CSLFIHDRJSTULR-JOCHJYFZSA-N
-
Cite this record
CBID:154735 http://www.chembase.cn/molecule-154735.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid
|
|
|
IUPAC Traditional name
|
2-{3-[(3S)-1-{[(4-isopropylphenyl)methoxy]carbonyl}piperidin-3-yl]phenoxy}-2-methylpropanoic acid
|
|
|
Synonyms
|
(S)-2-(3-(1-((4-Isopropylbenzyloxy)carbonyl)piperidin-3-yl)phenoxy)-2-methylpropanoic acid
|
CP-868388
|
N-[3-(4-Chlorophenyl)-3-[4-(2-thiazolylcarbonyl)phenoxy]propyl]-N-methylglycine Hydrochloride Hydrate
|
CP-802079 Hydrochloride Hydrate
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
3.8241458
|
H Acceptors
|
4
|
H Donor
|
1
|
LogD (pH = 5.5)
|
3.997944
|
LogD (pH = 7.4)
|
2.4256952
|
Log P
|
5.676822
|
Molar Refractivity
|
123.1499 cm3
|
Polarizability
|
47.979145 Å3
|
Polar Surface Area
|
76.07 Å2
|
Rotatable Bonds
|
8
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
TRC
Sigma Aldrich -
PZ0149
|
Legal Information Sold for research purposes under agreement from Pfizer Inc. Biochem/physiol Actions CP-868388 is a potent PPARα agonist with a Ki of 10.8 nM. |
Toronto Research Chemicals -
C781390
|
CP-802079 is a potent and selective glycine transporter type 1 (GlyT1) antagonist. Antagonists of GlyT1 increase levels of glycine in the synaptic cleft and, like direct glycine site agonists, they can augment NMDAR currents and NMDAR-mediated functions. |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Attwell, D., et al.: Neuron, 11, 401 (1993)
- • Grabs, D., et al.: J. Biol. Chem., 272, 13419 (1993)
- • Billups, D., et al.: Eur. J. Neurosci., 18, 2975 (1993)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent